Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 64
Semaglutide in India: the paediatric gap
Indian generic semaglutide has adult non-inferiority data. A 2026 letter in Indian Pediatrics asks what expanded access means for adolescents.
Compounders hold on in the GLP-1 market
A June 2026 Gallup survey found nearly 1 in 5 GLP-1 users still take compounded versions, despite FDA crackdowns and pharma lawsuits.
GLP-1 and opioid overdose risk in veterans
A 2026 VHA study linked semaglutide and tirzepatide to lower overdose rates than insulin and SGLT2 inhibitors in veterans with T2D and opioid use disorder.
NVAC charter, GLP-1 telehealth: July 2026
NVAC gets a new charter on 7 July 2026, LifeMD faces GLP-1 telehealth allegations, and Medicare proposes 19% more pay for tobacco counselling.
TTT1: triple therapy for type 1 diabetes
The TTT1 Phase 3 trial tests semaglutide and dapagliflozin added to insulin in overweight adults with type 1 diabetes and poor glycaemic control.
Surgery vs semaglutide: Reddit concerns
NLP of 45,972 Reddit comments: surgery patients cite pain; semaglutide users cite GI and psychological effects. Pre-op anxiety runs 4x higher than post-op.
Semax and Selank: normal, N-Acetyl, Amidate
N-Acetyl and Amidate caps extend peptide half-life by blocking degradation, not by changing the receptor mechanism. Here is the biochemistry.
LifeMD GLP-1 safety claims and Iowa's PBM
Former LifeMD employees allege GLP-1 prescriptions were rushed. An Iowa audit found a PBM may have overcharged Medicaid by over $100 million.
Tesamorelin in Sweden: regulatory status
Tesamorelin has no EU marketing authorisation. The EMA application was withdrawn in 2012. What the Swedish MPA position means for access.
BPC-157 and TB-500 while on a GLP-1 agonist
No published study has examined BPC-157 or TB-500 combined with a GLP-1 agonist. Both are unapproved drugs; the interaction picture is unknown.
Cagrilinitide without a GLP-1: the evidence
Cagrilinitide is an amylin analogue. Phase 2 data show 8.1% weight loss as monotherapy, but GI side effects run similar to semaglutide.
Tesamorelin in Sweden: import rules
Tesamorelin has no EU authorisation. Swedish Customs bars personal imports from outside the EEA. Here is what that means in practice.